The MISTIE III (Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation) trial was recently completed. MISTIE III, an international phase 3 clinical trial, was part of a long-term, ongoing effort to define a successful treatment for ICH.

• The MISTIE III trial is the culmination of the thrombolysis program spanning over 20 years of work by the trial Principal Investigators (PIs).
• The MISTIE III intervention seeks to remove blood from the brain through minimally invasive surgery and intermittent dosing of alteplase. The study premise is that by removing the blood clot faster than natural removal, injury to the brain will be reduced and the patient’s long-term prognosis will improve.
• The results of the MISTIE III trial were just presented as a late-breaking session at the 2019 ISC in Honolulu in February and published in The Lancet.

During the webinar, hear from MISTIE study experts:

• Dr. Dan Hanley, the PI from the trial, will review the history of the MISTIE studies and the results of the primary and secondary outcomes.
• Dr. Issam Awad, the Surgical PI, will review surgical considerations.
• Dr. Wendy Ziai will discuss the safety of thrombolysis in the setting of ICH.
• Dr. George Lopez will summarize the impact of these data on current clinical practice.

Objectives:

• Interpret the results from the MISTIE trial
• Construct a rational approach to the patient with an ICH
• Evaluate the comparative effectiveness of minimally invasive ICH therapies
• Recommend future steps in the study and surgical treatment of ICH